Influenza

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Research, Medicare, Influenza, Treatment, European Directive on Traditional Herbal Medicinal Products, New Drug Application, Centers for Medicare & Medicaid Services, Fungal infection, Translation, DFC, CHMP, Committee for Medicinal Products for Human Use, CDTX, European Medicines Agency, Invasive candidiasis, EMA, Safety, CD73, Therapy, Patient, European Commission, ATM, Respect, Committee, Conference, NTAP, New Shrimadhopur DFC Station, Janssen Pharmaceuticals, Tavarua, FDA, IND, EC, Senior, Johnson & Johnson, CMS, SAN, Pharmaceutical industry, Vaccine, Cryptocurrency, Security (finance), Janssen, Mundipharma, Melinta Therapeutics

Nicole is a practicing oncology physician and joins us from Genentech/Roche where she has had substantial cancer-focused product development experience.

Key Points: 
  • Nicole is a practicing oncology physician and joins us from Genentech/Roche where she has had substantial cancer-focused product development experience.
  • Presented at IDWeek 2023: In September 2023, Cidara delivered an oral presentation and two poster presentations highlighting the safety and efficacy of CD388.
  • For the nine months ended September 30, 2023 and 2022, net loss was $17.3 million and $16.4 million, respectively.
  • During the three months ended September 30, 2023, Cidara did not sell shares of common stock pursuant to its at-the-market (ATM) sales agreement.

Predictive Analysis Demonstrates a Combined Threat of Flu, RSV, and COVID-19 this Winter

Retrieved on: 
Thursday, November 2, 2023
BlueDot, RSV, RISE, Influenza, Atmosphere, FLU, PCR, EPA, Pregnancy, COVID-19, Research and development, School, Reckitt, Ventilation, Infection, Pharmaceutical industry, Sales, Vaccine, Research

PARSIPPANY, N.J., Nov. 2, 2023 /PRNewswire/ -- With winter on the horizon, predictive analysis conducted for Reckitt's Lysol Pro Solutions by data experts at BlueDot Inc.1 suggests that U.S. businesses should anticipate a concurrent rise in flu, RSV, and COVID-19 this year, but that the onset of respiratory virus season will be closer to typical pre-pandemic timing than last year.

Key Points: 
  • This year, signs from the southern hemisphere suggest that the flu season is trending towards pre-pandemic patterns.
  • Businesses can therefore leverage this predictability to ensure they are ramping up protection measures with appropriate timing.
  • RSV IS ON THE RISE AND IMPACTING CHILDREN IN PARTICULAR:
    Children in the southern hemisphere have already been affected by RSV in their winter season.
  • For more information about Lysol Pro Solutions or BlueDot, and for inquiries on how we can help your business, please contact:

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Retrieved on: 
Thursday, October 26, 2023
Urinary tract infection, FDA, NYSE, Food, BioNTech, Vaccine, SARS-CoV-2, FAAM, GMT, MD, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Influenza, Senior, Pfizer, Vaccination, Clinical trial, COVID-19, Risk, Viral, Head, BNTX, Safety, PFE, Immunization, Patient

In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

Key Points: 
  • In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.
  • The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
  • “We are encouraged by these early results in our Phase 1/2 study of our combination vaccine candidates against influenza and COVID-19.
  • Pfizer and BioNTech previously announced that their mRNA-based combination vaccine candidate for influenza and COVID-19 received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Retrieved on: 
Thursday, October 26, 2023
COVID-19, Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Urinary tract infection, FDA, NYSE, Food, BioNTech, Vaccine, SARS-CoV-2, FAAM, GMT, MD, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Influenza, Senior, Pfizer, Vaccination, Inc., Clinical trial, Risk, Viral, Head, BNTX, Safety, PFE, Immunization, Patient

In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.

Key Points: 
  • In the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.
  • The data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
  • “We are encouraged by these early results in our Phase 1/2 study of our combination vaccine candidates against influenza and COVID-19.
  • Pfizer and BioNTech previously announced that their mRNA-based combination vaccine candidate for influenza and COVID-19 received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

World Emerging Infectious Disease Diagnostics Market Research Report 2023: Respiratory Infections Take Center Stage in Infectious Disease Diagnostics Post-COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Infectious Diseases, Health, Other Health, RSV, Region, Infection, Chlamydia, Respiratory syncytial virus, SARS-CoV-2, Government, Urinary tract infection, Influenza, CRISPR, Ebola, PCR, Developed country, Virus, Virulence, POCT, Whole genome sequencing, Growth, Point-of-care testing, STI, NGS, Streptococcus, RT-LAMP, COVID-19, Mumps, Hospital, Gonorrhea, WGS, Polymerase chain reaction, Bacteria, Rubella, Hepatitis, Syphilis, Tuberculosis, Diagnosis, Gastroenteritis, Zika fever, POC, Pharmaceutical industry, Vaccine, Medical imaging, Medical device

The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.

Key Points: 
  • The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide.
  • North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market.
  • Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
  • Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.

DHSS launches interactive statewide flu dashboard

Retrieved on: 
Friday, October 13, 2023
Missouri Department of Health and Senior Services, Health, COVID-19, Antibody, Advisory Committee on Immunization Practices, Food, Death, Vaccine, Cough, Influenza-like illness, Food and Drug Administration, Hospital, Advisory Committee, Immunization, CDC, Safety, Season, Missouri Department of Social Services, Education, Vaccination, DHSS, Virus, Data, Fever, Infection, Influenza, RSV, Patient, Management, The Missourians

It is available as an interactive online dashboard , launched today.

Key Points: 
  • It is available as an interactive online dashboard , launched today.
  • The first week of this official flu season, Oct. 1-7, showed low flu activity with 125 laboratory-confirmed cases of influenza A and B reported statewide.
  • The dashboard streamlines the previous weekly flu reports , which DHSS has produced for many years during each official flu season (October through mid-May).
  • “This dashboard is another example of our continued commitment to modernizing the data we collect, analyze and share with Missourians,” said DHSS Director Paula F. Nickelson.

Longhorn Vaccines and Diagnostics Presents Data Demonstrating Durability of LHNVD-105 Universal Influenza Vaccine in Animal Models at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Veterinary, Health, Vaccine, Immunoglobulin G, Public, Antibody, ELISA, Immunity, Pig, Influenza B virus, Epitope, Peptide, Group 1, Infection, Influenza, Isotype, Diagnosis, MD, H1N1, Matrix

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.
  • The data was presented at IDWeek 2023, which took place in Boston from October 11-15, 2023.
  • Traditional seasonal influenza vaccines attempt to match circulating influenza strains.
  • Alternate vaccine strategies that target multiple key components of the virus that are conserved across influenza viruses have the potential to combat this issue.

New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

Retrieved on: 
Wednesday, October 11, 2023
Incidence, Health, COVID-19, Public, ASX, CSL, Outcome, Death, Season, Influenza, Vaccination, Person, Immunization, ICU, Vaccine

The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.

Key Points: 
  • The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.
  • from October 11-15, 2023.
  • "Observing an ever-growing set of real-world outcomes is critical to ensuring that cell-based influenza vaccine technology continues to push public health forward."
  • "With the 2023/24 Northern Hemisphere influenza season underway, we're committed to working with our partners in public health to help demonstrate the importance of vaccination for our communities and health systems, particularly following a significant drop in flu immunization rates since the COVID-19 pandemic."

American Lung Association Invests in Critical Work to Create Universal Flu Shot

Retrieved on: 
Wednesday, October 4, 2023
Partnership, American Lung Association, Texas Biomedical Research Institute, Disbursement Acceleration Program, Research, Doctor of Philosophy, Canadian Lung Association, Government, CDC, Death, Influenza, Korea Disease Control and Prevention Agency, Pharmaceutical industry, Vaccine

CHICAGO, Oct. 4, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced a three-year, $500,000 grant to Texas Biomedical Research Institute to help accelerate its efforts to develop a universal flu vaccine. This is the first Accelerator Program investment that the Lung Association has made since it launched the American Lung Association Research Institute earlier this year.

Key Points: 
  • CHICAGO, Oct. 4, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced a three-year, $500,000 grant to Texas Biomedical Research Institute to help accelerate its efforts to develop a universal flu vaccine.
  • This is the first Accelerator Program investment that the Lung Association has made since it launched the American Lung Association Research Institute earlier this year.
  • "This partnership with the American Lung Association enables us to move quickly with this vaccine research."
  • This funding was provided by the American Lung Association Research Institute, which launched in March to address the urgent and critical lung health challenges in our country.

Aging Wellness Fall Expo Celebrates Healthy and Active Lifestyles at Red Rock Casino Resort & Spa

Retrieved on: 
Tuesday, September 26, 2023
Honey, Well, Exercise, Snack, Senior, Allergy, Greeting, Las Vegas Review-Journal, Pulitzer Prize, Health, The Honey Baked Ham Company, Moon, Privacy, The Center, LAS, Red Rock Casino, Resort & Spa, Medicare, Expo, Ageing, Season, Influenza, Patient, Coffee, RN, News, Wellness, Casino, Nightclub, Optum

LAS VEGAS, Sept. 26, 2023 /PRNewswire/ -- Nevada's largest Aging Wellness Expo for active adults 50+ returns for the first seasonal event of the year. The Expo, powered by the Las Vegas Review-Journal and presented by Optum - Nevada, heads to Red Rock Casino Resort & Spa on Saturday, Sept. 30, 2023, from 9 a.m. to 3 p.m. Access to health, financial, and home improvement companies and countless resources are free for attendees. Early bird arrivals can enjoy coffee and, in the afternoon, sample healthy snacks.  Top experts and speakers are scheduled throughout the day to present topics such as healthy living, preventative screenings, benefits of exercise for seniors, and Medicare basics.

Key Points: 
  • LAS VEGAS, Sept. 26, 2023 /PRNewswire/ -- Nevada's largest Aging Wellness Expo for active adults 50+ returns for the first seasonal event of the year.
  • YMCA Health and Wellness Director Jonathan Jimenez will lead various exercise demonstrations at the Center Well Senior Primary Care Active Lounge inside the Red Rock Main Ballroom throughout the day.
  • The next Aging Wellness Spring Expo is scheduled for March 2, 2024, at South Point Hotel Casino and Spa.
  • Also, follow Aging Wellness on the Review-Journal's Facebook for news and information on 50+ active lifestyles.